About us ?

Investors and Partners

The company is actively supported by a solid network of financial, scientific and industrial partners.

Divider text here
  • Investors
  • VitamFero has successfully conducted several private placements. The company's shares are currently held by its founders, a group of business angels, Parisian and regional seed and venture capital funds and family and industrial funds.

AMAZING FEATURES

Divider text here
Praesent turpis tortor, posuere at nisl at, tincidunt condimentum ligula. Fusce purus tortor, ornare quis lectus eu, lacinia faucibus lorem. Aenean ac mi elementum libero semper porttitor. Aenean in dui ut urna feugiat suscipit at vel dolor.
Curabitur sit amet lorem et nunc varius sodales nec et leo. Vivamus sagittis turpis vel nisl facilisis, sed placerat odio ultricies. Suspendisse dolor lorem, faucibus eu tortor ac, hendrerit dapibus mi. Nam sed nunc ac magna
  • Aenean eget mi eget
  • Sed arcu eros lacinia
  • Duis dictum purus
  • Integer sodales justo
  • Etiam in sem et lectus
Curabitur sit amet lorem et nunc varius sodales nec et leo. Vivamus sagittis turpis vel nisl facilisis, sed placerat odio ultricies. Suspendisse dolor lorem, faucibus eu tortor ac, hendrerit dapibus mi. Nam sed nunc ac magna
  • Financial partners
  • The company is supported by many regional and national organizations commited to promoting innovation (i.e. BPI France, FranceAgriMer Atlanpole Biotherapy, Polepharma ...), by local authorities (Région Centre Val de Loire, département Indre & Loire) and by the European Union. ..

  • Scientific partners
  • VitamFero concluded and continues to build science partnerships. Historically, the vaccine technology, largely developed by VitamFero has since been developed and patented jointly by the CNRS, INRA and François Rabelais University of Tours. It has also developed partnerships with the Institut Pasteur, Cellectis Agrosup Dijon and the University of Bourgogne (Dijon).

  • Industrial partners
  • Recently VitamFero concluded an industrial partnership with the Australian company Bioproperties to ensure the launch of its first product: the vaccine against ovine toxoplasmosis which registration is scheduled from 2019 in New Zealand.